LLY vs QTTB: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

LLY is the larger of the two ($1.20T market cap): the incumbent the market prices for continued execution (26.59x forward earnings, beta 0.39). QTTB is the smaller challenger ($251.36M), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, QTTB fits: analysts expect its revenue to rise 150% next year, against 16% for LLY. If you believe in profit, LLY fits: it is expected to make money next year (26.59x forward earnings), while QTTB is still expected to post a loss.

LLY vs QTTB: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricLLYQTTBWhat it tells you
Market cap$1.20T$251.36MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E26.59-8.24Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E43.902.33Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.39-0.11Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range80% of range30% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book29.930.87How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how LLY and QTTB affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and QTTB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and QTTB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Eli Lilly (LLY) do?

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

What does Q32 Bio (QTTB) do?

Q32 Bio Inc. is a clinical-stage biotechnology company focused on alopecia areata (AA) and other autoimmune and inflammatory diseases. Its lead and effectively only clinical program is bempikibart (ADX-914), a fully human monoclonal antibody that blocks the interleukin-7 receptor alpha chain and therefore shuts down signaling from both IL-7 and TSLP, two pathways implicated in the T-cell attack on hair follicles. The company reached the public market by reverse-merging into Homology Medicines in March 2024, which is why the CIK on EDGAR still carries the old FIXX ticker, and it trades on the Nasdaq Capital Market with about 25 employees under CEO Jodie Morrison. Its history since then has been a sequence of narrowing decisions: bempikibart missed in atopic dermatitis (the SIGNAL-AD trial, topline December 2024), the company restructured in February 2025 to focus on AA, and in November 2025 it sold the entire ADX-097 complement program to Akebia Therapeutics. What remains is bempikibart, a preclinical half-life-extended follow-on called ADX-914-XL, and a retained tissue-targeted complement platform (ADX-096 and related molecules) that management describes as under strategic review.

Full QTTB guide

LLY vs QTTB: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
  • QTTB drivers: Bempikibart and the path to a registration-directed program; A balance sheet that now outlasts the next trial.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For QTTB, the concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025.

LLY or QTTB: which should you pick?

If the story you believe is LLY's (GLP-1 obesity and diabetes leadership), LLY is the more direct way to own it; if it is QTTB's (Bempikibart and the path to a registration-directed program), QTTB is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and QTTB guides.

LLY vs QTTB: the full fundamentals

LLY. At about $1,353 a share on November 20, 2026, Eli Lilly is valued near $1.2 trillion, roughly 44x trailing earnings and 27x the roughly $50.87 in EPS analysts expect for 2027. That premium rests on revenue growth near 39% in the latest quarter and margins (about 51% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the mean analyst target of about $1,470 sits roughly 9% above the price.

QTTB. Operating figures are approximate and drawn from the November 4, 2026 third-quarter release, the Q2 2026 10-Q and the fiscal 2025 10-K; market figures are as of the 2026-11-20 close. Check live data before acting on any of them. Two screen-level numbers on QTTB are misleading and worth discarding: the ~2.3x trailing P/E and the ~4.7x price-to-sales both derive from the ~$53.7 million of one-time non-cash collaboration revenue and the ~$29.8 million of 2025 net income it produced, and neither describes an operating business. The number that carries information is enterprise value, which was roughly ~$276 million in August and has since fallen to around zero once the ~$290 million of cash is netted against the ~$303 million fully-funded equity value. That is what the market is now assigning to bempikibart, the retained complement platform and the Akebia royalty stream combined, a level that typically signals skepticism about the data or an expectation that much of the cash will be spent before value is proven.

Headline figures (approximate, November 2026): LLY shows revenue (ttm) ~$86.5 billion, q3 2026 revenue ~$24.4 billion (up ~39% YoY), q3 2026 eps $7.48 vs ~$6.35 est., gross / operating margin (ttm) ~84% / ~51%; QTTB shows revenue (ttm) ~$53.7 million, all of it recognized in the fourth quarter of 2025 and none of it product revenue: it is the derecognition of a ~$55.0 million refund liability from the terminated Horizon collaboration, settled with Amgen on November 7, 2025 for ~553,695 shares. Revenue in the first nine months of 2026 was ~$0, latest quarter (q3 2026) Net loss ~$8.9 million, EPS -$0.26 vs ~-$0.33 expected; no revenue. R&D ~$5.1 million, G&A ~$5.5 million. Consensus sees a ~$0.28 loss per share in Q4 2026, loss rate Net losses of ~$7.6 million, ~$9.0 million and ~$8.9 million in the first three quarters of 2026; Yahoo Finance shows ~-$20 million of trailing operating cash flow. Accumulated deficit was ~$221.5 million at June 30, 2026, cash and runway ~$289.6 million of cash at September 30, 2026, no venture debt. Management states this funds operations through topline Phase 3 results of the planned registration-directed program, and explicitly not through regulatory approval.

The bottom line: LLY vs QTTB

LLY and QTTB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined LLY and QTTB exposure against your real portfolio. It is not an investment adviser.

Wondering how LLY or QTTB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Eli Lilly

Ask Walnut's AI anything about LLY and see how it fits what you own.

FAQ

What is the difference between LLY and QTTB?

+

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Q32 Bio Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is LLY or QTTB the better stock?

+

Neither is universally better. LLY is the larger incumbent; QTTB is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, LLY or QTTB?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both LLY and QTTB?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of LLY vs QTTB?

+

LLY: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. The balance sheet has also become more leveraged as Lilly funds capacity: debt was about $49.5 billion against about $4.9 billion of cash at September 30, 2026, and trailing free cash flow of about $9.3 billion is far below operating cash flow of about $30.7 billion because of heavy capital spending. Revenue growth also slowed from about 48% in the second quarter to about 39% in the third as the base gets larger, and GAAP net income fell quarter over quarter, so the pace of growth is now part of the debate. QTTB: The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. The July data came from an open-label single-arm trial of 33 patients with no placebo control, and the headline numbers rest on a 25-patient mITT population, so eight of the 33 enrolled patients sit outside the primary analysis and the ITT figures are materially lower (~30.3% versus ~40.0% on SALT20); alopecia areata trials have a long history of placebo responses and spontaneous regrowth that a single-arm design cannot separate out. The economics of a future partnership are encumbered, because bempikibart is in-licensed from Bristol-Myers Squibb under a 2019 agreement that entitles BMS to development and regulatory milestones of ~$32 million to ~$49 million per indication for the first three indications, up to ~$215 million of commercial milestones, royalties from mid-single digits to ~10%, and up to ~60% of any sublicense income, a share that falls only as the program advances. Dilution has been continuous and is not finished: the share count went from ~12.9 million at the end of 2025 to ~29.8 million by August 3, 2026 through a February registered direct, a March ATM with Cantor Fitzgerald, a May private placement at $8.00 and the July follow-on at $18.25, there are ~6.1 million pre-funded warrants outstanding on top of that, and the company states plainly that its cash will not carry any program to regulatory approval. Finally, the listing itself has been fragile before, with a May 19, 2025 Nasdaq notice for falling below the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1) that was only cured on the strength of the Q4 2025 accounting gain and subsequent raises, and a stock that ranged from ~$1.62 to ~$23.57 within twelve months is not one where position sizing is a detail. The past four months make the point: the shares fell from ~$23.57 on July 14 to ~$8.42 on 2026-11-20, well below the $18.25 July offering price and close to the $8.00 May placement price, despite additional supportive data at EADV and a narrower-than-expected third-quarter loss.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LLY or QTTB; figures are approximate and dated (as of November 2026). Verify current data before investing.